Stereotactic body radiation therapy for prostate cancer: Is the technology ready to be the standard of care?

Nicholas G. Zaorsky, Matthew Thomas Studenski, Adam P. Dicker, Leonard Gomella, Robert B. Den

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Prostate cancer is the second most prevalent solid tumor diagnosed in men in the United States and Western Europe. Stereotactic body radiation therapy (SBRT) is touted as a superior type of external beam radiation therapy (EBRT) for the treatment of various tumors. SBRT developed from the theory that high doses of radiation from brachytherapy implant seeds could be recapitulated from advanced technology of radiation treatment planning and delivery. Moreover, SBRT has been theorized to be advantageous compared to other RT techniques because it has a treatment course shorter than that of conventionally fractionated EBRT (a single session, five days per week, for about two weeks vs. eight weeks), is non-invasive, is more effective at killing tumor cells, and is less likely to cause damage to normal tissue. In areas of the US and Europe where there is limited access to RT centers, SBRT is frequently being used to treat prostate cancer, even though long-term data about its efficacy and safety are not well established. We review the impetus behind SBRT and the current clinical evidence supporting its use for prostate cancer, thus providing oncologists and primary care physicians with an understanding of the continually evolving field of prostate radiation therapy. Studies of SBRT provide encouraging results of biochemical control and late toxicity. However, they are limited by a number of factors, including short follow-up, exclusion of intermediate- and high-risk patients, and relatively small number of patients treated. Currently, SBRT regimens should only be used in the context of clinical trials.

Original languageEnglish (US)
Pages (from-to)212-218
Number of pages7
JournalCancer Treatment Reviews
Volume39
Issue number3
DOIs
StatePublished - May 2013
Externally publishedYes

Fingerprint

Standard of Care
Prostatic Neoplasms
Radiotherapy
Technology
Radiation
Neoplasms
Brachytherapy
Primary Care Physicians
Prostate
Seeds
Therapeutics
Clinical Trials
Safety

Keywords

  • Hypofractionation
  • Prostate cancer
  • Quality of life
  • Radiotherapy
  • Stereotactic body radiation therapy
  • Toxicity

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Stereotactic body radiation therapy for prostate cancer : Is the technology ready to be the standard of care? / Zaorsky, Nicholas G.; Studenski, Matthew Thomas; Dicker, Adam P.; Gomella, Leonard; Den, Robert B.

In: Cancer Treatment Reviews, Vol. 39, No. 3, 05.2013, p. 212-218.

Research output: Contribution to journalArticle

Zaorsky, Nicholas G. ; Studenski, Matthew Thomas ; Dicker, Adam P. ; Gomella, Leonard ; Den, Robert B. / Stereotactic body radiation therapy for prostate cancer : Is the technology ready to be the standard of care?. In: Cancer Treatment Reviews. 2013 ; Vol. 39, No. 3. pp. 212-218.
@article{bf8b608cfbc94627a571a7ee447b1245,
title = "Stereotactic body radiation therapy for prostate cancer: Is the technology ready to be the standard of care?",
abstract = "Prostate cancer is the second most prevalent solid tumor diagnosed in men in the United States and Western Europe. Stereotactic body radiation therapy (SBRT) is touted as a superior type of external beam radiation therapy (EBRT) for the treatment of various tumors. SBRT developed from the theory that high doses of radiation from brachytherapy implant seeds could be recapitulated from advanced technology of radiation treatment planning and delivery. Moreover, SBRT has been theorized to be advantageous compared to other RT techniques because it has a treatment course shorter than that of conventionally fractionated EBRT (a single session, five days per week, for about two weeks vs. eight weeks), is non-invasive, is more effective at killing tumor cells, and is less likely to cause damage to normal tissue. In areas of the US and Europe where there is limited access to RT centers, SBRT is frequently being used to treat prostate cancer, even though long-term data about its efficacy and safety are not well established. We review the impetus behind SBRT and the current clinical evidence supporting its use for prostate cancer, thus providing oncologists and primary care physicians with an understanding of the continually evolving field of prostate radiation therapy. Studies of SBRT provide encouraging results of biochemical control and late toxicity. However, they are limited by a number of factors, including short follow-up, exclusion of intermediate- and high-risk patients, and relatively small number of patients treated. Currently, SBRT regimens should only be used in the context of clinical trials.",
keywords = "Hypofractionation, Prostate cancer, Quality of life, Radiotherapy, Stereotactic body radiation therapy, Toxicity",
author = "Zaorsky, {Nicholas G.} and Studenski, {Matthew Thomas} and Dicker, {Adam P.} and Leonard Gomella and Den, {Robert B.}",
year = "2013",
month = "5",
doi = "10.1016/j.ctrv.2012.10.003",
language = "English (US)",
volume = "39",
pages = "212--218",
journal = "Cancer Treatment Reviews",
issn = "0305-7372",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Stereotactic body radiation therapy for prostate cancer

T2 - Is the technology ready to be the standard of care?

AU - Zaorsky, Nicholas G.

AU - Studenski, Matthew Thomas

AU - Dicker, Adam P.

AU - Gomella, Leonard

AU - Den, Robert B.

PY - 2013/5

Y1 - 2013/5

N2 - Prostate cancer is the second most prevalent solid tumor diagnosed in men in the United States and Western Europe. Stereotactic body radiation therapy (SBRT) is touted as a superior type of external beam radiation therapy (EBRT) for the treatment of various tumors. SBRT developed from the theory that high doses of radiation from brachytherapy implant seeds could be recapitulated from advanced technology of radiation treatment planning and delivery. Moreover, SBRT has been theorized to be advantageous compared to other RT techniques because it has a treatment course shorter than that of conventionally fractionated EBRT (a single session, five days per week, for about two weeks vs. eight weeks), is non-invasive, is more effective at killing tumor cells, and is less likely to cause damage to normal tissue. In areas of the US and Europe where there is limited access to RT centers, SBRT is frequently being used to treat prostate cancer, even though long-term data about its efficacy and safety are not well established. We review the impetus behind SBRT and the current clinical evidence supporting its use for prostate cancer, thus providing oncologists and primary care physicians with an understanding of the continually evolving field of prostate radiation therapy. Studies of SBRT provide encouraging results of biochemical control and late toxicity. However, they are limited by a number of factors, including short follow-up, exclusion of intermediate- and high-risk patients, and relatively small number of patients treated. Currently, SBRT regimens should only be used in the context of clinical trials.

AB - Prostate cancer is the second most prevalent solid tumor diagnosed in men in the United States and Western Europe. Stereotactic body radiation therapy (SBRT) is touted as a superior type of external beam radiation therapy (EBRT) for the treatment of various tumors. SBRT developed from the theory that high doses of radiation from brachytherapy implant seeds could be recapitulated from advanced technology of radiation treatment planning and delivery. Moreover, SBRT has been theorized to be advantageous compared to other RT techniques because it has a treatment course shorter than that of conventionally fractionated EBRT (a single session, five days per week, for about two weeks vs. eight weeks), is non-invasive, is more effective at killing tumor cells, and is less likely to cause damage to normal tissue. In areas of the US and Europe where there is limited access to RT centers, SBRT is frequently being used to treat prostate cancer, even though long-term data about its efficacy and safety are not well established. We review the impetus behind SBRT and the current clinical evidence supporting its use for prostate cancer, thus providing oncologists and primary care physicians with an understanding of the continually evolving field of prostate radiation therapy. Studies of SBRT provide encouraging results of biochemical control and late toxicity. However, they are limited by a number of factors, including short follow-up, exclusion of intermediate- and high-risk patients, and relatively small number of patients treated. Currently, SBRT regimens should only be used in the context of clinical trials.

KW - Hypofractionation

KW - Prostate cancer

KW - Quality of life

KW - Radiotherapy

KW - Stereotactic body radiation therapy

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84873994847&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873994847&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2012.10.003

DO - 10.1016/j.ctrv.2012.10.003

M3 - Article

C2 - 23218442

AN - SCOPUS:84873994847

VL - 39

SP - 212

EP - 218

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

SN - 0305-7372

IS - 3

ER -